Company news
Laekna, Inc. news in 2024
Laekna, Inc.'s news releases, calls and decks from 2024, newest first.
Laekna Announces Poster Presentation on Internally Discovered Selective PI3Kα Inhibitor at SABCS 2024
December 11, 2024
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity
November 20, 2024
Laekna Announces FDA Approval for the Phase III Clinical Trial Protocol of LAE002 (Afuresertib) PLUS LAE001 for the Treatment of Prostate Cancer
May 23, 2024
Laekna Releases 2023 ESG Report
April 29, 2024
Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024
January 3, 2024